DL-AP5 (lithium)

• Description :

  DL-AP5 (2-APV) lithium is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 lithium shows significantly antinociceptive activity. DL-AP5 lithium specifically blocks on channels in the rabbit retina[1][2][3].

• Product Name Alternative :

  2-APV (lithium) ; DL-2-Amino-5-phosphonovaleric acid (lithium)

• UNSPSC :

  12352211

• Target :

  IGluR

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Field of Research :

  Inflammation/Immunology; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/dl-ap5-lithium.html

• Solubility :

  10 mM in DMSO

• Smiles :

  NC(CCCP(O)(O)=O)C(O[Li])=O

• Molecular Formula :

  C5H11LiNO5P

• Molecular Weight :

  203.06

• References & Citations :

  [1]Murray CW, et al. Neurokinin and NMDA antagonists (but not a kainic acid antagonist) are antinociceptive in the mouse formalin model. Pain. 1991;44 (2) :179-185.|[2]Massey SC, et al. N-methyl-D-aspartate receptors of ganglion cells in rabbit retina. J Neurophysiol. 1990;63 (1) :16-30.|[3]Jafari-Sabet M. NMDA receptor blockers prevents the facilitatory effects of post-training intra-dorsal hippocampal NMDA and physostigmine on memory retention of passive avoidance learning in rats. Behav Brain Res. 2006 Apr 25;169 (1) :120-7.|[4]Taati M, et al. The effects of DL-AP5 and glutamate on ghrelin-induced feeding behavior in 3-h food-deprived broiler cockerels. J Physiol Biochem. 2011 Jun;67 (2) :217-23.|[5]Chen T, et al. Glutamate-induced rapid induction of Arc/Arg3.1 requires NMDA receptor-mediated phosphorylation of ERK and CREB. Neurosci Lett. 2017 Nov 20;661:23-28.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  NMDA Receptor

• CAS Number :

  [125229-62-1]